Physician profile
Michael E Galloway
NPI 1780654913
$1,461.69
in general payments reported to CMS, 2019-2025
22 companies · $648 in 2025
The $648 reported for 2025 was more than what 79% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $188 · 2022: $93.86 · 2023: $105 · 2024: $238 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $977 · Education: $13.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.20 |
| Education | $13.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $210.57 | 2019-2024 | Spaceoar Vue System - 10ml |
| Novartis Pharmaceuticals Corporation | $197.49 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $136.13 | 2023-2025 | Onglyza |
| Geron Corporation | $121.66 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $116.93 | 2019-2025 | |
| Janssen Biotech, INC. | $104.45 | 2022-2025 | Tecvayli, Darzalex, Erleada |
| Astellas Pharma US INC | $73.44 | 2019 | |
| Merck Sharp & Dohme LLC | $73.37 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $63.10 | 2020-2025 | |
| Horizon Therapeutics Plc | $52.07 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $50.29 | 2025 | Polivy, Venclexta |
| Exelixis INC. | $48.11 | 2024-2025 | Cabometyx |
| Incyte Corporation | $38.86 | 2024-2025 | Jakafi |
| Acrotech Biopharma INC. | $29.62 | 2025 | Beleodaq |
| Glaxosmithkline, LLC. | $29.24 | 2024 | Zejula |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $20.59 | 2025 | Mi Cancer Seek |
| Dendreon Pharmaceuticals LLC | $17.86 | 2019 | |
| Clovis Oncology, INC. | $17.38 | 2022 | |
| Blue Earth Diagnostics | $16.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.01 | 2025 | Opdualag |
| Sumitomo Pharma America, INC. | $14.77 | 2025 | Orgovyx |
| Pfizer INC. | $14.39 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Galloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.